Press Release   -

Non Alcoholic Steatohepatitis (NASH) Market Projected to Reach USD 21,879 Million by 2028

The Non Alcoholic Steatohepatitis (NASH) Market is expected to reach USD 21,879 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 60.4% from 2022 to 2028. The increasing demand for the ideal NASH therapeutics, the surge in prevalence of NASH all over the globe coupled with the expected launch of pipeline drugs are factors driving the market growth. Additionally, rising awareness of NASH in emerging economies is another expected to boost the market demand.

Key Findings:

• The off-label drugs sub-segment of drug classes segment is holding a dominant position in the market. The current NASH drugs market is current scenario is occupied by off-label drugs because there are no such clinically approved medicines for the treatment of NASH. Certain therapeutic drugs are expected to enter the market from large pharmaceutical drugs in the coming years. The requirement of definitive NASH treatment would result in strong market penetration of therapeutic drugs over the forecasted period.
• North America is accounted for the largest share of the Market during the projected years. The growing adoption of sedentary lifestyles as well as consumption of junk & processed food among the global population causing several health problems and diseases are factors driving the Market.

The major players involved in the development of Market are - Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc..

The growth in the Market is driven by an increase in healthcare expenditure, the growing prevalence of diabetic population in developed and developing nations, growth in pharmaceutical research & development with rising funding in the same coupled with the rising number of obese populations. Apart from these, growth in the market penetration for NASH major drugs, NASH pipeline drugs under development, progress in NASH diagnosis methods & biomarkers are factors offering new opportunities to the market. Additionally, e-commerce pharmaceutical products sales are gaining high importance and boosting market demand all over the globe. However, the market growth is majorly challenged by delay in the drug approval processes, higher treatment cost, less definitive diagnostic methods for NASH/NAFLD, reimbursement limit for prohibitively priced therapies coupled with lack of proper diagnostic techniques are factors expected to hinder the market growth.

Asia Pacific has the potential to have substantial growth in the coming years. The rising prevalence of several diseases in the region is producing favorable growth opportunities for many drug companies. The increasing prevalence of liver disease in countries like the U.S and Canada is driving market demand. The Canadian Liver Foundation stated that non-alcoholic fatty liver disease (NAFLD) is projected to very common condition in North America. The major manufacturer companies in the region are focusing heavily on research activities for the development of novel drugs for treatment.